600 Participants Needed

Rotarex Atherectomy for Peripheral Artery Disease

Recruiting at 1 trial location
AS
TS
Overseen ByTalar Saber
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: C. R. Bard
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores a new treatment for individuals with peripheral artery disease, a condition that reduces blood flow to the legs. The treatment employs the Rotarex Rotational Excisional Atherectomy System, a device designed to remove blockages in blood vessels. Suitable candidates for this trial have leg artery blockages treatable with this device and experience symptoms like leg pain or difficulty walking. The trial aims to evaluate the treatment's effectiveness and gather information on its safety. As an unphased trial, participants can contribute to pioneering research that may lead to new treatment options for peripheral artery disease.

Do I have to stop taking my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What prior data suggests that the Rotarex(TM) Rotational Excisional Atherectomy System is safe for treating Peripheral Artery Disease?

Research has shown that the Rotarex™ Rotational Excisional Atherectomy System is generally well-tolerated. In the iDissection study, two cases of blockages occurred due to debris, with one linked to the Rotarex system. Fortunately, both cases were treated successfully without lasting issues.

The Rotarex system is a minimally invasive tool that effectively removes plaque and blood clots from leg arteries, helping to open blocked blood vessels.

While no serious side effects have been reported, minor complications can occur. Overall, the system appears safe based on current research. However, discussing potential risks with a doctor before joining any trial is important.12345

Why are researchers excited about this trial?

Unlike traditional treatments for Peripheral Artery Disease (PAD), which often involve stents or bypass surgery, the Rotarex(TM) Rotational Excisional Atherectomy System offers a minimally invasive approach. This device works by physically removing plaque from the arteries rather than just compressing it against the artery wall. Researchers are excited about this system because it can potentially reduce recovery time and lower the risk of complications associated with more invasive procedures. Additionally, the Rotarex system aims to improve blood flow more effectively by directly excising the blockage, offering a promising alternative for patients with PAD.

What evidence suggests that the Rotarex(TM) Rotational Excisional Atherectomy System is effective for Peripheral Artery Disease?

Studies have shown that the Rotarex™ Rotational Excisional Atherectomy System effectively treats peripheral artery disease (PAD). This system clears plaque and blood clots from the arteries, restoring blood flow. One study found that patients with femoropopliteal arterial disease treated with this system experienced positive outcomes. Specifically, after 12 months, 92.3% of these patients had clear arteries, indicating a high success rate. Overall, the Rotarex™ system shows promise for improving blood flow in people with PAD.12346

Who Is on the Research Team?

PK

Prakash Krishnan, MD, FACC

Principal Investigator

The Icahn School of Medicine, The Mount Sinai Health System

TL

Todd L Berland, MD, FACS

Principal Investigator

NYU Langone Health

Are You a Good Fit for This Trial?

This trial is for adults over 22 with Peripheral Arterial Disease who have specific types of chronic or acute limb ischemia. Participants must have a lesion treatable by the Rotarex system, be able to cross the lesion with a guidewire, and have at least one unblocked artery to the foot (for chronic cases). Consent is required.

Inclusion Criteria

I or my legal representative have signed the consent form.
I am 22 years old or older.
I have a blockage in my leg arteries that can be treated with a specific device.
See 3 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Subjects are treated with the Rotarex(TM) Rotational Excisional Atherectomy System

Immediate

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Rotarex(TM) Rotational Excisional Atherectomy System

Trial Overview

The XTRACT Registry study is observing how well the Rotarex(TM) System works in real-world settings for patients with arterial blockages in their legs. It's a single-group study meaning everyone gets this treatment; there's no comparison group.

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Rotarex(TM) Rotational Excisional Atherectomy SystemExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

C. R. Bard

Lead Sponsor

Trials
109
Recruited
40,200+

Timothy M. Ring

C. R. Bard

Chief Executive Officer since 2003

Bachelor of Science in Industrial and Labor Relations from Cornell University

Dr. Cimler

C. R. Bard

Chief Medical Officer since 2017

Ph.D. in Pharmacology

Citations

Rotarex™ Rotational Excisional Atherectomy System

The Rotarex™ Atherectomy System is designed to efficiently remove both plaque and thrombus by utilizing three distinct mechanisms of action to treat PAD lesions ...

2.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/39575214/

Results of the iDissection Rotarex Study

Conclusions: The Rotarex device is an effective atherectomy device in treating complex femoropopliteal arterial disease. A high frequency of ...

BD to Initiate Real-World Patient Data Registry for the ...

The Rotarex™ Atherectomy System is a minimally invasive solution designed to efficiently remove both plaque and thrombus in peripheral arteries.

Results of the iDissection Rotarex Study

The Rotarex device is an effective atherectomy device in treating complex femoropopliteal arterial disease. A high frequency of adventitial ...

Peripheral Atherectomy and Thrombectomy Devices

At 12-months follow-up, the primary clinical success/patency rate was 92.3 % and the secondary clinical success/patency rate was 91.4 %. Rate of limb salvage ...

BD to initiate real-world patient registry for Rotarex ...

BD has plans to initiate a patient data registry for the Rotarex atherectomy system to measure real-world outcomes in patients with PAD.